Infection

Siemens Zika test receives FDA emergency use authorization

The U.S. Food and Drug Administration (FDA) has granted Siemens Healthcare Diagnostics Inc. (Siemens) an Emergency Use Authorization (EUA) for its real-time PCR Zika Virus assay, the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit. With respect to Zika in vitro diagnostic tests, FDA has been authorized to issue EUAs to allow for use of unapproved medical products or unapproved uses of approved medical products when, among other circumstances, there are no adequate, approved, and available alternatives and certain additional criteria are met.

Photo: Siemens Zika test receives FDA emergency use authorization

“The FDA’s emergency use authorization of the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit from Siemens can lead us one step closer to stopping the spread of the Zika virus,” says Fernando Beils, Vice President, Head of Molecular Diagnostics, Siemens . “Being able to quickly diagnose patients will help physicians to more efficiently manage those affected.”

The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit is capable of detecting the presence of Zika virus, which can be an earlier indicator of Zika virus infection than anti-Zika antibodies. The molecular test is validated for plasma, serum, and urine (collected alongside a patient-matched serum or plasma specimen) from individuals meeting CDC Zika virus clinical criteria and/or CDC Zika virus epidemiological criteria, and is designed to run on the Siemens VERSANT® kPCR Sample Prep automated platform, along with several commercially available thermal cyclers. The assay must be run by laboratories in the United States that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories. The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit has not been FDA cleared or approved and is only authorized for use for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection.
 
Click here for more information on the FDA’s EUA for Siemens’ VERSANT Zika RNA 1.0 Assay (kPCR).


[i] http://www.fda.gov/EmergencyPreparedness/Counterterrorism/ucm182568.htm

Source: Siemens Healthcare Diagnostics

02.08.2016

Related articles

Photo

Sponsored • Earlier disease prediction and identification

The potential of AI in routine blood testing

It’s widely known that more than 70% of today’s medical decisions involve the results of laboratory tests, but the insights clinicians derive from these tests today may only be scratching the…

Photo

Sponsored • Siemens Naeotom Alpha

First CT scanner with photon-counting technology

Conventional CT imaging has reached its technical limitations: Resolution can only be improved by small margins and dose cannot be reduced significantly: Photon-counting technology enables drastic…

Photo

Sponsored • Photon-counting CT scanner

No detours, more detail

For the Siemens Healthineers team developing new and ever higher performing computed tomographs is daily fare. But when they introduced their most recent CT system an unusual sense of pride was…

Related products

Subscribe to Newsletter